Skip to Content

Tivicay

Generic Name: Dolutegravir Sodium
Class: HIV Integrase Inhibitors
Chemical Name: (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide sodium salt
Molecular Formula: C20H18F2N3NaO5
CAS Number: 1051375-19-9

Medically reviewed on Oct 1, 2018

Warning

    Fixed Combination of Abacavir, Dolutegravir, and Lamivudine
  • If using abacavir/dolutegravir/lamivudine (Triumeq), consider that abacavir has been associated with serious and sometimes fatal hypersensitivity reactions, with multiple organ failure involvement.240 Individuals with the human leukocyte antigen (HLA)-B*5701 allele are at higher risk for abacavir hypersensitivity reactions, although such reactions have occurred in those without the HLA-B*5701 allele.240 Contraindicated in patients who are HLA-B*5701 positive and in those with prior hypersensitivity reaction to abacavir.240 Screen all patients for HLA-B*5701 allele prior to initiation or reinitiation of abacavir/dolutegravir/lamivudine, unless patient has previously documented HLA-B*5701 allele assessment.240 Immediately discontinue abacavir/dolutegravir/lamivudine if hypersensitivity reaction suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.240 Following a hypersensitivity reaction, never reinitiate abacavir/dolutegravir/lamivudine or any other abacavir-containing preparation because more severe reactions, including death, can occur within hours.240 Similar severe reactions also reported rarely following reintroduction of abacavir-containing preparation in patients with no history of abacavir hypersensitivity.240

  • If using abacavir/dolutegravir/lamivudine, consider that lactic acidosis and severe hepatomegaly with steatosis, including fatalities, reported in patients receiving HIV nucleoside reverse transcriptase inhibitors (NRTIs) in conjunction with other antiretrovirals.240 Discontinue if clinical or laboratory findings suggest lactic acidosis or pronounced hepatotoxicity.240

  • If using abacavir/dolutegravir/lamivudine, consider that severe, acute exacerbations of HBV reported following discontinuance of lamivudine in HIV-infected patients coinfected with HBV.240 Monitor hepatic function with both clinical and laboratory follow-up for at least several months after discontinuance of lamivudine-containing preparations in coinfected patients.240 If appropriate, initiation of HBV treatment may be warranted.240

Introduction

See also: Atripla

Antiretroviral; HIV integrase strand transfer inhibitor (INSTI).1 200

Uses for Tivicay

Treatment of HIV Infection

Treatment of HIV-1 infection in adults, adolescents, and pediatric patients weighing ≥30 kg;1 2 3 4 5 6 22 23 33 usually used in conjunction with 2 HIV NRTIs (dual NRTIs).1 200 201

For initial treatment in antiretroviral-naive adults and adolescents, experts state that dolutegravir in conjunction with tenofovir alafenamide and emtricitabine or dolutegravir in conjunction with tenofovir disoproxil fumarate (tenofovir DF) and emtricitabine (or lamivudine) are recommended INSTI-based regimens.200 Dolutegravir in conjunction with abacavir and lamivudine (or emtricitabine) also is a recommended INSTI-based regimen for initial treatment, but use only in those who are HLA-B*5701 negative.200

For initial treatment in antiretroviral-naive pediatric patients, experts state that an INSTI-based regimen of dolutegravir in conjunction with 2 NRTIs is a preferred regimen in those ≥6 years of age weighing ≥30 kg.201

In antiretroviral-experienced adults and adolescents, dolutegravir usually used in INSTI-based regimens that include dolutegravir and an optimized background antiretroviral regimen (OBR).1 6 22 23 240

In certain virologically suppressed antiretroviral-experienced adults (i.e., those with plasma HIV-1 RNA levels <50 copies/mL on a stable antiretroviral regimen for ≥6 months who have no known history of treatment failure and are infected with HIV-1 with no known substitutions associated with resistance to dolutegravir or rilpivirine), a 2-drug regimen of dolutegravir and rilpivirine can be used to replace the current regimen.1 247 If the 2-drug regimen is used in such adults, single-entity dolutegravir and single-entity rilpivirine can be used concomitantly1 or the commercially available fixed combination of dolutegravir and rilpivirine (dolutegravir/rilpivirine; Juluca) can be used.247

Fixed combination containing abacavir, dolutegravir, and lamivudine (abacavir/dolutegravir/lamivudine; Triumeq) is used alone or in conjunction with other antiretrovirals in adults, adolescents, and pediatric patients weighing ≥40 kg.240 Do not use abacavir/dolutegravir/lamivudine alone in patients with suspected or confirmed INSTI-resistance substitutions;240 dosage of dolutegravir in the fixed combination insufficient in such patients.240

Postexposure Prophylaxis following Nonoccupational Exposure to HIV (nPEP)

Postexposure prophylaxis of HIV infection following nonoccupational exposure (nPEP) in individuals exposed to blood, genital secretions, or other potentially infectious body fluids that might contain HIV when the exposure represents a substantial risk for HIV transmission.198 Used in conjunction with other antiretrovirals.198

When nPEP indicated in adults and adolescents ≥13 years of age with normal renal function, CDC states preferred regimen is either raltegravir or dolutegravir used in conjunction with emtricitabine and tenofovir DF (given as emtricitabine/tenofovir DF; Truvada);198 recommended alternative in these patients is ritonavir-boosted darunavir used in conjunction with emtricitabine/tenofovir DF.198

Consult infectious disease specialist, clinician with expertise in administration of antiretroviral agents, and/or the National Clinicians’ Postexposure Prophylaxis Hotline (PEPline at 888-448-4911) if nPEP indicated in certain exposed individuals (e.g., pregnant women, children, those with medical conditions such as renal impairment) or if considering a regimen not included in CDC guidelines, source virus is known or likely to be resistant to antiretrovirals, or healthcare provider is inexperienced in prescribing antiretrovirals.198 Do not delay initiation of nPEP while waiting for expert consultation.198

Tivicay Dosage and Administration

Administration

Oral Administration

Dolutegravir (Tivicay): Administer orally once or twice daily without regard to food.1 Use in conjunction with other antiretrovirals.1

Abacavir/dolutegravir/lamivudine (Triumeq): Administer orally once daily without regard to food.240 Use alone as a complete treatment regimen or use in conjunction with other antiretrovirals.240

Do not use single-entity dolutegravir and abacavir/dolutegravir/lamivudine concomitantly, unless needed for adjustment of dolutegravir dosage (e.g., when fixed combination used concomitantly with efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, or rifampin).240 When abacavir/dolutegravir/lamivudine and single-entity dolutegravir both indicated, give daily dose of the fixed combination and daily dose of the single-entity preparation 12 hours apart.240

Dosage

Dolutegravir (Tivicay): Available as dolutegravir sodium; dosage expressed in terms of dolutegravir.1

Abacavir/dolutegravir/lamivudine (Triumeq): Contains abacavir sulfate, dolutegravir sodium, and lamivudine;240 dosages of abacavir and dolutegravir components expressed in terms of the bases.240

A film-coated tablet containing abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg taken in fasted state is bioequivalent to a 50-mg dolutegravir tablet taken simultaneously with a fixed-combination tablet containing abacavir 600 mg and lamivudine 300 mg (abacavir/lamivudine) in fasted state.21 240

Pediatric Patients

Treatment of HIV Infection
Antiretroviral-naive Pediatric Patients
Oral

Dolutegravir in children and adolescents weighing 30 to <40 kg: 35 mg once daily (one 25-mg tablet and one 10-mg tablet once daily).1

Dolutegravir in children and adolescents weighing 30 to <40 kg receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 35 mg twice daily (one 25-mg tablet and one 10-mg tablet twice daily).1

Dolutegravir in children and adolescents weighing ≥40 kg: 50 mg once daily.1

Dolutegravir in children and adolescents weighing ≥40 kg receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 50 mg twice daily.1

Abacavir/dolutegravir/lamivudine in pediatric patients weighing ≥40 kg: 1 tablet (600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine) once daily.240

Abacavir/dolutegravir/lamivudine in pediatric patients weighing ≥40 kg receiving certain drugs (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 1 tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and a 50-mg tablet of single-entity dolutegravir once daily given 12 hours after the daily dose of the fixed combination.240

Antiretroviral-experienced Pediatric Patients
Oral

Dolutegravir in children and adolescents weighing 30 to <40 kg: 35 mg once daily (one 25-mg tablet and one 10-mg tablet once daily).1

Dolutegravir in children and adolescents weighing 30 to <40 kg receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 35 mg twice daily (one 25-mg tablet and one 10-mg tablet twice daily).1

Dolutegravir in children and adolescents weighing ≥40 kg who are antiretroviral-experienced, INSTI-naive: 50 mg once daily.1

Dolutegravir in children and adolescents ≥40 kg who are antiretroviral-experienced, INSTI-naive, and receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 50 mg twice daily.1

Dolutegravir: Safety and efficacy not established in INSTI-experienced pediatric patients with documented or clinically suspected resistance to other INSTIs (e.g., elvitegravir, raltegravir).1

Abacavir/dolutegravir/lamivudine in pediatric patients weighing ≥40 kg: 1 tablet (600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine) once daily.240 Do not use alone in those with clinically suspected or confirmed INSTI-resistance substitutions.240

Abacavir/dolutegravir/lamivudine in pediatric patients weighing ≥40 kg receiving certain drugs (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 1 tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and a 50-mg tablet of single-entity dolutegravir once daily given 12 hours after the daily dose of the fixed combination.240

Adults

Treatment of HIV Infection
Antiretroviral-naive Adults
Oral

Dolutegravir: 50 mg once daily.1

Dolutegravir in adults receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 50 mg twice daily.1

Abacavir/dolutegravir/lamivudine: 1 tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily.240

Abacavir/dolutegravir/lamivudine in adults receiving certain drugs (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 1 tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and a 50-mg tablet of single-entity dolutegravir once daily given 12 hours after the daily dose of the fixed combination.240

Antiretroviral-experienced Adults
Oral

Dolutegravir in antiretroviral-experienced, INSTI-naive adults: 50 mg once daily.1

Dolutegravir in antiretroviral-experienced, INSTI-experienced adults with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg twice daily.1

Dolutegravir in antiretroviral-experienced adults receiving certain UGT1A or CYP3A inducers (i.e., efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 50 mg twice daily.1

Dolutegravir in conjunction with rilpivirine in certain antiretroviral-experienced adults (see Treatment of HIV Infection under Uses): 50 mg once daily with single-entity rilpivirine (25 mg once daily).1

Abacavir/dolutegravir/lamivudine in antiretroviral-experienced adults: 1 tablet (600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine) once daily.240 Do not use alone in those with clinically suspected or confirmed INSTI-resistance substitutions.240

Abacavir/dolutegravir/lamivudine in antiretroviral-experienced adults receiving certain drugs (efavirenz, ritonavir-boosted fosamprenavir, ritonavir-boosted tipranavir, carbamazepine, rifampin): 1 tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and a 50-mg tablet of single-entity dolutegravir once daily given 12 hours after the daily dose of the fixed combination.240

Postexposure Prophylaxis following Nonoccupational Exposure to HIV (nPEP)
Oral

Dolutegravir 50 mg once daily.198 Use in conjunction with 2 NRTIs (see Postexposure Prophylaxis following Nonoccupational Exposure to HIV [nPEP] under Uses).198

Initiate nPEP as soon as possible (within 72 hours) following nonoccupational exposure that represents a substantial risk for HIV transmission and continue for 28 days.198

nPEP not recommended if exposed individual seeks care >72 hours after exposure.198

Special Populations

Hepatic Impairment

Dolutegravir: Dosage adjustments not needed in patients with mild or moderate hepatic impairment (Child-Pugh class A or B);1 do not use in those with severe hepatic impairment (Child-Pugh class C).1 (See Hepatic Impairment under Cautions.)

Abacavir/dolutegravir/lamivudine: Do not use in patients with mild hepatic impairment (Child-Pugh class A) since reduction in abacavir dosage needed in such patients;240 contraindicated in those with moderate or severe hepatic impairment (Child-Pugh class B or C).240 (See Hepatic Impairment under Cautions.)

Renal Impairment

Dolutegravir: Dosage adjustments not needed in antiretroviral-naive or antiretroviral-experienced, INSTI-naive patients with mild, moderate, or severe renal impairment;1 dosage adjustments not needed in antiretroviral-experienced, INSTI-experienced patients with mild or moderate renal impairment.1 Use with caution in patients with severe renal impairment who are INSTI-experienced and have certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.1 10 Manufacturer makes no specific dosage recommendations regarding use in patients requiring dialysis.1 (See Renal Impairment under Cautions.)

Abacavir/dolutegravir/lamivudine: Do not use in patients with Clcr <50 mL/minute since reduction in lamivudine dosage needed in such patients.240 (See Renal Impairment under Cautions.)

Geriatric Patients

No specific dosage recommendations;1 use with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.1 (See Geriatric Use under Cautions.)

Cautions for Tivicay

Contraindications

  • Dolutegravir (Tivicay): Previous hypersensitivity reaction to dolutegravir;1 concomitant use with dofetilide.1 (See Specific Drugs under Interactions.)

  • Abacavir/dolutegravir/lamivudine (Triumeq): HLA-B*5701-positive or previous hypersensitivity reaction to abacavir (regardless of HLA-B*5701 status);240 previous hypersensitivity reaction to dolutegravir or lamivudine;240 concomitant use with dofetilide;240 moderate or severe hepatic impairment.240 Consider contraindications associated with each drug in the fixed combination.240 (See Precautions Related to Use of Fixed Combinations under Cautions.)

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions reported.1 Reactions include rash and constitutional findings and, occasionally, organ dysfunction including liver toxicity.1

Immediately discontinue dolutegravir, abacavir/dolutegravir/lamivudine, and any other suspect agents if signs or symptoms of hypersensitivity occur, including (but not limited to) severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters or peeling skin, oral blisters or lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema, or difficulty breathing.1 240 Monitor clinical status, including liver aminotransferases, and initiate appropriate therapy.1 240

Life-threatening reactions could occur if discontinuance of dolutegravir, abacavir/dolutegravir/lamivudine, and any other suspect agents is delayed after onset of hypersensitivity reaction.1 240

Hepatic Effects

Adverse hepatic effects reported in patients receiving dolutegravir-containing regimens.1 240

HIV-infected patients with HBV or HCV coinfection may be at increased risk for development or worsening of aminotransferase elevations.1 240 In some patients receiving a dolutegravir-containing regimen, serum aminotransferase elevations were consistent with immune reconstitution syndrome or HBV reactivation, particularly in the setting where HBV therapy had been discontinued.1 240

Cases of hepatic toxicity, including elevated serum liver biochemistries, hepatitis, and acute liver failure, also reported in patients receiving a dolutegravir-containing regimen who had no preexisting hepatic disease or other identifiable risk factors.1 240

Drug-induced liver injury leading to liver transplant reported with abacavir/dolutegravir/lamivudine.1 240

Monitor for hepatotoxicity.1 240

Fetal/Neonatal Morbidity and Mortality

Neural tube defects involving brain, spine, and spinal cord reported rarely in infants born to women who received dolutegravir.35 203 Preliminary results from an ongoing observational study indicate higher risk of neural tube defects in infants born to women who were receiving dolutegravir at time of conception or early in first trimester of pregnancy.35 203

Pending further accumulation of data, FDA and other experts recommend that women of childbearing potential undergo pregnancy testing before a dolutegravir-containing regimen is initiated and take measures to avoid pregnancy during treatment with such regimens.35 203 (See Pregnancy under Cautions.)

Interactions

Consider potential for drug interactions prior to and during treatment with dolutegravir or abacavir/dolutegravir/lamivudine and monitor for adverse effects associated with concomitant drugs.1 240

Concomitant use with certain drugs may result in drug interactions.1 May lead to loss of therapeutic effects and possible development of resistance or possible adverse effects from increased exposures of concomitant drugs.1

HIV-infected Individuals Coinfected with HBV or HCV

Increased risk for elevated serum aminotransferase concentrations.1 (See Hepatic Effects under Cautions.)

If abacavir/dolutegravir/lamivudine used in HIV-infected patients coinfected with HBV or HCV, consider that additional precautions apply to these coinfected patients.240 (See Precautions Related to Use of Fixed Combinations under Cautions.)

Precautions Related to Use of Fixed Combinations

Abacavir/dolutegravir/lamivudine: Consider cautions, precautions, contraindications, and drug interactions associated with each drug in the fixed combination.240 Consider cautionary information applicable to specific populations (e.g., pregnant or nursing women, individuals with hepatic or renal impairment, geriatric patients) for each drug.240

If abacavir/dolutegravir/lamivudine used, consider that abacavir associated with serious and sometimes fatal hypersensitivity reactions, including multiple organ failure and anaphylaxis.240 Individuals with the HLA-B*5701 allele are at higher risk for hypersensitivity reactions to abacavir, although such reactions reported in patients without the HLA-B*5701 allele.240 Review medical history for prior exposure to any abacavir-containing preparation.240 Screen all patients for the HLA-B*5701 allele prior to initiating or reinitiating abacavir/dolutegravir/lamivudine, unless patient has documentation of prior HLA-B*5701 allele assessment.240 Immediately discontinue abacavir/dolutegravir/lamivudine if a hypersensitivity reaction is suspected, regardless of patient's HLA-B*5701 status and even when other diagnoses are possible.240 Never restart abacavir/dolutegravir/lamivudine or any other abacavir-containing preparation in a patient who experienced a hypersensitivity reaction to an abacavir-containing preparation since more severe reactions can occur within hours and may include life-threatening hypotension and death.240 If hypersensitivity ruled out, manufacturer of abacavir/dolutegravir/lamivudine states that the drug may be reinitiated, but only if medical care is readily accessible.240 Since it is not possible to determine whether hypersensitivity reaction in patient receiving abacavir/dolutegravir/lamivudine is caused by abacavir or dolutegravir,240 never reinitiate abacavir-containing or dolutegravir-containing preparations in patients who stopped therapy with abacavir/dolutegravir/lamivudine due to a hypersensitivity reaction.240

If abacavir/dolutegravir/lamivudine used, consider that lactic acidosis and severe hepatomegaly with steatosis, including fatalities, reported in patients receiving HIV NRTIs alone or in conjunction with other antiretrovirals.240 Discontinue abacavir/dolutegravir/lamivudine if clinical or laboratory findings indicate lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked increases in serum aminotransferase concentrations.240

If abacavir/dolutegravir/lamivudine used in patients coinfected with HIV and HBV, consider that severe, acute exacerbations of HBV infection reported following discontinuance of lamivudine in coinfected patients.240 Closely monitor hepatic function (using both clinical and laboratory follow-up) for at least several months after abacavir/dolutegravir/lamivudine discontinued.240 If appropriate, initiation of HBV treatment may be warranted.240 Safety and efficacy of abacavir/dolutegravir/lamivudine not established for treatment of chronic HBV infection.240

Adipogenic Effects

Redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (“buffalo hump”), peripheral wasting, facial wasting, breast enlargement, and general cushingoid appearance reported in patients receiving antiretroviral therapy.240

Mechanisms and long-term consequences unknown;240 causal relationship not established.240

Immune Reconstitution Syndrome

During initial treatment, HIV-infected patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium, M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jirovecii [formerly P. carinii], varicella-zoster virus [VZV]);1 240 this may necessitate further evaluation and treatment.1 240

Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) also reported to occur in the setting of immune reconstitution;1 240 time to onset is more variable and can occur many months after initiation of antiretroviral therapy.1 240

Specific Populations

Pregnancy

Antiretroviral Pregnancy Registry at 800-258-4263 or [Web].1 202 240

Dolutegravir crosses placenta;202 results of an ex vivo perfusion model indicate high fetal-to-maternal ratio (0.6).202

Preliminary results from an ongoing observational study in Botswana indicate higher risk of neural tube defects in infants born to women receiving a dolutegravir-containing regimen at time of conception or early in first trimester of pregnancy.35 203 To date, no reported cases of neural tube defects in infants born to women who received dolutegravir initiated later in pregnancy.35 FDA is conducting a comprehensive review of these results and any other data that become available.35

Pending further accumulation of data, FDA and other experts recommend advising women of childbearing potential (including those already receiving a dolutegravir-containing regimen) about potential risk of neural tube defects if dolutegravir is taken near time of conception or early in first trimester of pregnancy and instructing such women to use effective contraception to avoid pregnancy during treatment.35 203 Neural tube defects can occur early in pregnancy35 within first 4 weeks (28 days) after conception or 6 weeks from last menstrual period.203

FDA and other experts recommend that a pregnancy test be performed in all women of childbearing potential prior to initiation of a dolutegravir-containing regimen.35 203 Experts recommend that dolutegravir not be initiated in pregnant women within 8 weeks of their last menstrual period.203 If a pregnant woman is already receiving a dolutegravir-containing regimen and is within 8 weeks of her last menstrual period, these experts recommend the healthcare provider counsel the woman about risks and benefits of the current regimen; if other options are available, a switch to a regimen that does not contain dolutegravir is recommended.203 If a woman is pregnant and 8 weeks past her last menstrual period, these experts state that initiating or continuing a dolutegravir-containing regimen or initiating or switching to a regimen that does not contain dolutegravir can be considered after weighing risks and benefits.203 Consult National Perinatal HIV Hotline at 888-448-8765 for additional guidance.203

Manufacturer states data insufficient to date to adequately assess risk of birth defects and miscarriage if dolutegravir or abacavir/dolutegravir/lamivudine used in pregnant women.1 240

Lactation

Not known whether dolutegravir distributed into human milk, affects milk production, or affects breast-fed infant.1

Some reports that dolutegravir distributed into human milk in low concentrations;202 distributed into milk in rats.1 202

Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.1 202

Pediatric Use

Dolutegravir (Tivicay): Safety and efficacy not established in pediatric patients weighing <30 kg;1 safety and efficacy not established in INSTI-experienced pediatric patients who have documented or suspected resistance to other HIV INSTIs (e.g., elvitegravir, raltegravir).1 Safety profile in children and adolescents 6 to <18 years of age similar to that in adults.1

Abacavir/dolutegravir/lamivudine (Triumeq): Do not use in pediatric patients weighing <40 kg; dosage adjustments cannot be made.240 Safety and efficacy in those weighing ≥40 kg is derived from pediatric trials using the individual components of the fixed combination.240

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether they respond differently to dolutegravir or abacavir/dolutegravir/lamivudine than younger adults.1 240

Caution advised because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1 240

Hepatic Impairment

Dolutegravir: Should not be used in patients with severe hepatic impairment (Child-Pugh class C);1 pharmacokinetics not evaluated in such patients.1 Pharmacokinetics in patients with moderate hepatic impairment similar to those in healthy individuals; dosage adjustments not needed in those with mild or moderate hepatic insufficiency (Child-Pugh class A or B).1 Risk for further elevations in hepatic enzyme concentrations in patients with HBV or HCV coinfection.1

Abacavir/dolutegravir/lamivudine: Should not be used in patients with mild hepatic impairment (Child-Pugh class A).240 Because decreased abacavir dosage is recommend in those with mild hepatic impairment,200 switch to the single-entity components to allow adjustment of abacavir dosage in such patients.240 Contraindicated in those with moderate or severe hepatic impairment (Child-Pugh class B or C).240

Renal Impairment

Dolutegravir: Use with caution in patients with severe renal impairment who are INSTI-experienced and have documented or suspected INSTI resistance;1 10 dolutegravir plasma concentrations decreased in such patients and may result in loss of therapeutic effects and development of resistance to the drug or other antiretrovirals.1

Dolutegravir: May be used in patients with mild or moderate renal impairment; no clinically important effect on dolutegravir pharmacokinetics.1 10 Dosage adjustments not needed in antiretroviral-naive or antiretroviral-experienced, INSTI-naive patients with mild, moderate, or severe renal impairment.1 10 Dosage adjustments not needed in INSTI-experienced patients with mild or moderate renal impairment.1

Not evaluated in dialysis patients;1 unlikely that renal replacement therapy would have clinically important effect on dolutegravir pharmacokinetics.10 (See Renal Impairment under Dosage and Administration.)

Dolutegravir increases Scr by inhibiting tubular secretion of creatinine;1 does not cause clinically important change in GFR or renal plasma flow.1

Abacavir/dolutegravir/lamivudine: Do not use if Clcr <50 mL/minute.240 Because lamivudine substantially eliminated by kidneys and decreased lamivudine dosage recommended in those with Clcr <50 mL/minute, switch to the single-entity components to allow adjustment of lamivudine dosage in such patients.240

Common Adverse Effects

Insomnia; headache; fatigue; diarrhea; hyperglycemia; decreased neutrophils; increased serum aminotransferases, total bilirubin, creatine kinase, lipase, and cholesterol.1

Interactions for Tivicay

CYP3A plays minor role in dolutegravir metabolism.1 8 9 Dolutegravir does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A;1 does not induce CYP1A2, 2B6, or 3A4.1

Metabolized by UGT1A1 and also is a substrate for UGT1A3 and UGT1A9.1 Does not inhibit UGT1A1 or UGT2B7.1

Substrate of P-glycoprotein (P-gp);1 does not inhibit P-gp-mediated transport.1

Substrate of breast cancer resistance protein (BCRP);1 does not inhibit BCRP.1

Inhibits multidrug and toxin extrusion transporter (MATE) 1.1

Inhibits renal organic anion transporter (OAT) 1 and OAT3.1 Does not inhibit organic anion transporter polypeptide (OATP) 1B1 or OATP1B3;1 not a substrate of OATP1B1 or 1B3.1

Inhibits renal organic cation transporter (OCT) 2;1 does not inhibit OCT1.1

Does not inhibit bile salt export pump (BSEP) or multidrug resistance protein (MRP) 2 or MRP4.1

The following drug interactions are based on studies using dolutegravir.1 Drug interaction studies not performed using abacavir/dolutegravir/lamivudine.240 When abacavir/dolutegravir/lamivudine is used, consider interactions associated with each drug in the fixed combination.240

Drugs Affecting Hepatic Microsomal Enzymes

CYP3A inducers: Possible decreased dolutegravir plasma concentrations and decreased therapeutic effects.1

CYP3A inhibitors: Possible increased dolutegravir plasma concentrations.1

Drugs Affecting Uridine Diphosphate-glucuronosyltransferases

UGT1A1, 1A3, or 1A9 inducers: Possible decreased dolutegravir plasma concentrations and decreased therapeutic effects.1

UGT1A1 inhibitors: Possible increased dolutegravir plasma concentrations.1

Drugs Affecting P-glycoprotein Transport

P-gp inducers: Possible decreased dolutegravir plasma concentrations.1

P-gp inhibitors: Possible increased dolutegravir plasma concentrations.1

Drugs Affecting Breast Cancer Resistance Protein

BCRP inducers: Possible decreased dolutegravir plasma concentrations.1

BCRP inhibitors: Possible increased dolutegravir plasma concentrations.1

Drugs Affected by Multidrug and Toxin Extrusion Transporter

Drugs eliminated by MATE1: Possible decreased plasma concentrations of these drugs.1

Drugs Affected by Renal Organic Cation Transporters

Drugs eliminated by OCT2: Possible increased plasma concentrations of these drugs.1

Specific Drugs

Drug

Interaction

Comments

Abacavir

No in vitro evidence of antagonistic antiretroviral effects1

Adefovir

No in vitro evidence of antagonistic antiviral effects1

Antacids, aluminum-, calcium-, or magnesium-containing

Decreased dolutegravir concentrations and AUC1 19 200 240

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after aluminum-, calcium-, or magnesium-containing antacids1 200 240

Antiarrhythmic agents (dofetilide)

Dofetilide: Possible increased dofetilide concentrations and increased risk of serious and/or life-threatening adverse effects1 240

Dofetilide: Concomitant use with dolutegravir or abacavir/dolutegravir/lamivudine contraindicated1 240

Anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin)

Carbamazepine: Decreased dolutegravir concentrations and AUC1 30

Oxcarbazepine, phenobarbital, phenytoin: Possible decreased dolutegravir concentrations1

Carbamazepine (adults): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive adults, use dolutegravir 50 mg twice daily;1 consider alternative anticonvulsant in INSTI-experienced adults with documented or suspected INSTI resistance;1 if abacavir/dolutegravir/lamivudine used, give 1 fixed-combination tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and a 50-mg tablet of single-entity dolutegravir once daily 12 hours after the fixed-combination dose240

Carbamazepine (pediatric patients): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive pediatric patients weighing 30 to <40 kg, use dolutegravir 35 mg twice daily;1 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 consider alternative anticonvulsant in INSTI-experienced patients with documented or suspected INSTI resistance1

Oxcarbazepine, phenobarbital, phenytoin: Avoid concomitant use with dolutegravir or abacavir/dolutegravir/lamivudine since data insufficient to make dosage recommendations;1 240 consider alternative anticonvulsant200

Antidiabetic agents (metformin)

Metformin: Increased metformin concentrations and AUC1 31 200

Metformin: Monitor blood glucose concentrations when dolutegravir or abacavir/dolutegravir/lamivudine is initiated or discontinued in patient receiving metformin1 31 200 240 and do not exceed metformin hydrochloride dosage of 1 g daily during concomitant therapy;1 200 240 experts state use low metformin dosage if initiated in patient receiving dolutegravir and titrate dosage to achieve glycemic control and minimize adverse GI effects200

Antimycobacterial agents (rifabutin, rifampin, rifapentine)

Rifabutin: No clinically important effects on dolutegravir pharmacokinetics1 200

Rifampin: Decreased dolutegravir concentrations and AUC1 200

Rifapentine: Decreased dolutegravir concentrations expected200

Rifabutin: Dosage adjustments not needed200

Rifampin (adults): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive adults, use dolutegravir 50 mg twice daily;1 200 consider alternative to rifampin (e.g., rifabutin) in INSTI-experienced adults with documented or suspected INSTI resistance;1 200 if abacavir/dolutegravir/lamivudine used, give 1 fixed-combination tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and give a 50-mg tablet of single-entity dolutegravir once daily 12 hours after the fixed-combination dose240

Rifampin (pediatric patients): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive pediatric patients weighing 30 to <40 kg, use dolutegravir 35 mg twice daily;1 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 consider alternative to rifampin (e.g., rifabutin) in INSTI-experienced patients with documented or suspected INSTI resistance1

Rifapentine: Experts state do not use concomitantly with dolutegravir200

Atazanavir

Ritonavir-boosted atazanavir or unboosted atazanavir: Increased dolutegravir concentrations and AUC; no effects on atazanavir pharmacokinetics1 200

Cobicistat-boosted atazanavir: Data not available200

Cobicistat-boosted, ritonavir-boosted, or unboosted atazanavir: Dosage adjustments not needed1 200

Buffered preparations

Buffered preparations containing polyvalent cations: Possible decreased dolutegravir concentrations1

Buffered preparations containing polyvalent cations: Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after such preparations;1 200 240

Calcium supplements

Possible decreased dolutegravir concentrations when used concomitantly in the fasted state1 28

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after oral calcium supplements;1 28 200 240 alternatively, may be given concomitantly if taken with food1 28 200 240

Corticosteroids

Prednisone: No clinically important effects on dolutegravir pharmacokinetics1 8

Prednisone: Dosage adjustments not needed1

Daclatasvir

No clinically important pharmacokinetic interactions with dolutegravir1

Dosage adjustments not needed1

Darunavir

Ritonavir-boosted darunavir: Decreased dolutegravir concentrations and AUC; no effects on darunavir pharmacokinetics1 200

Cobicistat-boosted darunavir: Clinically important interactions not expected 237

Cobicistat-boosted or ritonavir-boosted darunavir: Dosage adjustments not needed1 200

Efavirenz

Decreased dolutegravir concentrations and AUC1 26 200

No in vitro evidence of antagonistic antiretroviral effects1

Dolutegravir (adults): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive, use dolutegravir 50 mg twice daily;1 200 in INSTI-experienced adults with documented or suspected INSTI resistance, consider alternative to efavirenz whenever possible1 200

Dolutegravir (pediatric patients): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive pediatric patients weighing 30 to <40 kg, use dolutegravir 35 mg twice daily;1 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 in INSTI-experienced patients with documented or suspected INSTI resistance, consider alternative to efavirenz whenever possible1

Abacavir/dolutegravir/lamivudine (adults): Give 1 fixed-combination tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and give a 50-mg tablet of single-entity dolutegravir once daily 12 hours after the fixed-combination dose240

Elbasvir and grazoprevir

Fixed combination of elbasvir and grazoprevir (elbasvir/grazoprevir): No clinically important effects on pharmacokinetics of elbasvir, grazoprevir, or dolutegravir1 177

Dosage adjustments not needed if used with dolutegravir1 177

Enfuvirtide

No in vitro evidence of antagonistic antiretroviral effects1

Etravirine

Substantially decreased dolutegravir concentrations and AUC1 200

Effect on dolutegravir pharmacokinetics is mitigated if etravirine and dolutegravir used concomitantly with lopinavir/ritonavir or ritonavir-boosted darunavir;1 200 effect expected to be mitigated if etravirine and dolutegravir used concomitantly with ritonavir-boosted atazanavir1 200

Do not use etravirine and dolutegravir or abacavir/dolutegravir/lamivudine concomitantly unless ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or lopinavir/ritonavir also included in the regimen1 200 240

In antiretroviral-naive or antiretroviral-experienced, INSTI-naive patients without INSTI resistance: Use dolutegravir 50 mg once daily with etravirine and with ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or lopinavir/ritonavir200

INSTI-experienced with documented or suspected INSTI resistance: Use dolutegravir 50 mg twice daily with etravirine and with ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or lopinavir/ritonavir200

Estrogens/progestins

Estradiol, estrogen, conjugated estrogens: Dolutegravir may have variable effects on estrogen concentrations200

Drospirenone, medroxyprogesterone, progesterone: Pharmacokinetic interactions with dolutegravir not expected200

Oral contraceptives containing ethinyl estradiol and norgestimate: Dolutegravir has no effect on pharmacokinetics of ethinyl estradiol or norgestimate1 29

Estradiol, estrogen, conjugated estrogens: Dosage adjustments not needed200

Drospirenone, medroxyprogesterone, progesterone: Dosage adjustments not needed200

Oral contraceptives containing ethinyl estradiol and norgestimate: Dosage adjustments not needed200

Finasteride

Pharmacokinetic interactions with dolutegravir not expected200

Dosage adjustments not needed200

Fosamprenavir

Ritonavir-boosted fosamprenavir: Decreased dolutegravir concentrations and AUC;1 27 effect on fosamprenavir pharmacokinetics unlikely1 27

No in vitro evidence of antagonistic antiretroviral effects with amprenavir (active metabolite of fosamprenavir)1

Ritonavir-boosted fosamprenavir (adults): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive adults, use dolutegravir 50 mg twice daily;1 in INSTI-experienced adults with documented or suspected INSTI resistance, consider alternative to ritonavir-boosted fosamprenavir whenever possible;1 if abacavir/dolutegravir/lamivudine used, give 1 fixed-combination tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and give a 50-mg tablet of single-entity dolutegravir once daily 12 hours after the fixed-combination dose240

Ritonavir-boosted fosamprenavir (pediatric patients): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive pediatric patients weighing 30 to <40 kg, use dolutegravir 35 mg twice daily;1 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 in INSTI-experienced patients with documented or suspected INSTI resistance, consider alternative to ritonavir-boosted fosamprenavir whenever possible1

Glecaprevir and pibrentasvir

Fixed combination of glecaprevir and pibrentasvir (glecaprevir/pibrentasvir): No clinically important pharmacokinetic interactions with dolutegravir200

Dosage adjustments not needed200

Goserelin

Pharmacokinetic interactions with dolutegravir not expected200

Dosage adjustments not needed200

Iron preparations

Possible decreased dolutegravir concentrations when used concomitantly in the fasted state1 28

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after oral iron;1 28 200 240 alternatively, may be given concomitantly if taken with food1 28 200 240

Laxatives containing polyvalent cations

Possible decreased dolutegravir concentrations1

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after laxatives containing polyvalent cations1 200 240

Ledipasvir and sofosbuvir

Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): No clinically important pharmacokinetic interactions if used with dolutegravir181 200

Dosage adjustments not needed200

Leuprolide

Pharmacokinetic interactions with dolutegravir not expected200

Dosage adjustments not needed200

Lopinavir/ritonavir

No clinically important effects on dolutegravir pharmacokinetics1 200

No in vitro evidence of antagonistic antiretroviral effects1

Dosage adjustments not needed200

Maraviroc

No in vitro evidence of antagonistic antiretroviral effects1

Methadone

No clinically important effect on methadone pharmacokinetics1 200

Dosage adjustments not needed1 200

Midazolam

No clinically important effect on midazolam pharmacokinetics1 18 200

Dosage adjustments not needed1 200

Multivitamins

Possible decreased dolutegravir concentrations1

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after multivitamins containing calcium or iron;1 200 240 alternatively, may be given concomitantly if taken with food1 240

Nevirapine

Decreased dolutegravir concentrations and AUC1 200

No in vitro evidence of antagonistic antiretroviral effects1

Manufacturer states do not use concomitantly with dolutegravir or abacavir/dolutegravir/lamivudine;1 200 240 data insufficient to make dosage recommendations1 240

Experts state dosage adjustments not needed200

Proton-pump inhibitors

Omeprazole: No clinically important effect on dolutegravir pharmacokinetics1 19

Omeprazole or other proton-pump inhibitors: Dosage adjustments not needed200

Raltegravir

No in vitro evidence of antagonistic antiretroviral effects1

Ribavirin

No in vitro evidence of antagonistic antiviral effects1

Rilpivirine

No clinically important effect on rilpivirine or dolutegravir pharmacokinetics1 200

Dosage adjustments not needed200

Ritonavir

Effect on ritonavir pharmacokinetics unlikely1

St. John's wort (Hypericum perforatum)

Decreased dolutegravir concentrations1

Avoid concomitant use with dolutegravir or abacavir/dolutegravir/lamivudine1 240

Simeprevir

Clinically important interactions with dolutegravir not expected187 200

Dosage adjustments not needed200

Sofosbuvir

Clinically important pharmacokinetics interactions with dolutegravir not expected200

Dosage adjustments not needed200

Sofosbuvir and velpatasvir

Fixed combination of sofosbuvir and velpatasvir (sofosbuvir/velpatasvir): No clinically important pharmacokinetic interactions with dolutegravir176

Dosage adjustments not needed1

Sofosbuvir, velpatasvir, and voxilaprevir

Fixed combination of sofosbuvir, velpatasvir, and voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir): Clinically important pharmacokinetic interactions with dolutegravir not expected200

Dosage adjustments not needed200

Spironolactone

Clinically important pharmacokinetic interactions not expected if used with dolutegravir200

Dosage adjustments not needed200

SSRIs

Citalopram or other SSRIs: Clinically important pharmacokinetic interactions not expected200

Citalopram or other SSRIs: Dosage adjustments not needed200

Stavudine

No in vitro evidence of antagonistic antiretroviral effects1

Sucralfate

Possible decreased dolutegravir concentrations1

Give dolutegravir or abacavir/dolutegravir/lamivudine ≥2 hours before or ≥6 hours after sucralfate1 200 240

Tenofovir

Tenofovir alafenamide or tenofovir DF: No clinically important effect on tenofovir or dolutegravir pharmacokinetics1 200

Tenofovir alafenamide or tenofovir DF: Dosage adjustments not needed200

Testosterone

Clinically important pharmacokinetic interactions not expected if used with dolutegravir200

Dosage adjustments not needed200

Tipranavir

Ritonavir-boosted tipranavir: Decreased dolutegravir concentrations and AUC1 26 200

Ritonavir-boosted tipranavir (adults): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive adults, use dolutegravir 50 mg twice daily;1 200 in INSTI-experienced adults with documented or suspected INSTI resistance, consider alternative to ritonavir-boosted tipranavir whenever possible;1 200 if abacavir/dolutegravir/lamivudine used, give 1 fixed-combination tablet (abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg) once daily and give a 50-mg tablet of single-entity dolutegravir once daily 12 hours after the fixed-combination dose240

Ritonavir-boosted tipranavir (pediatric patients): In antiretroviral-naive or antiretroviral-experienced, INSTI-naive pediatric patients weighing 30 to <40 kg, use dolutegravir 35 mg twice daily;1 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 in INSTI-experienced patients with documented or suspected INSTI resistance, consider alternative to ritonavir-boosted tipranavir whenever possible1

Tivicay Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability of dolutegravir not established.1

Dolutegravir (Tivicay): Following 50 mg orally once or twice daily, peak plasma concentrations occur 2–3 hours after a dose.1 Steady state achieved within approximately 5 days with once-daily dosing.1

Food

Dolutegravir: Administration with high-fat meal increases AUC by 66%, increases peak concentrations by 67%, and prolongs time to peak concentrations from 2 hours to 5 hours compared with administration in fasting state.1

Abacavir/dolutegravir/lamivudine (Triumeq): Administration with high-fat meal increases dolutegravir peak plasma concentrations and AUC by 37 and 48%, respectively, compared with administration in fasting state;240 abacavir peak plasma concentrations decreased by 23%;240 lamivudine exposures not affected.240

Distribution

Extent

Dolutegravir distributed into CSF;1 32 clinical importance unknown.1

Crosses placenta.202

Appears to be distributed into human milk in low concentrations;202 distributed into milk in rats.1

Plasma Protein Binding

≥98.9%.1

Elimination

Metabolism

Dolutegravir metabolized primarily by UGT1A1;1 CYP3A plays minor role.1

Elimination Route

Dolutegravir excreted in feces (53%) and urine (31%).1

Half-life

Approximately 14 hours.1

Special Populations

Moderate hepatic impairment: No clinically important effect on dolutegravir pharmacokinetics.1

Severe hepatic impairment: Dolutegravir pharmacokinetics not studied.1

HCV coinfection: No clinically important effect on dolutegravir pharmacokinetics.1

Mild to moderate renal impairment: No clinically important effect on dolutegravir pharmacokinetics.1

Severe renal impairment (Clcr <30 mL/minute): Dolutegravir AUC decreased by 40%;1 peak plasma concentration decreased by 23%.1 (See Renal Impairment under Cautions.)

Polymorphism in UGT1A1: Genotypes of UGT1A1 conferring poor dolutegravir metabolism result in 32% lower clearance and 46% higher AUC compared with genotypes associated with normal UGTIA1 metabolism.1

HIV-1-infected pediatric patients weighing >30 kg: Pharmacokinetic profile of dolutegravir similar to HIV-1-infected adults receiving dolutegravir 50 mg once daily.1

Stability

Storage

Oral

Tablets

Dolutegravir (Tivicay): 25°C (may be exposed to 15–30°C).1

Abacavir/dolutegravir/lamivudine (Triumeq): 25°C (may be exposed to 15–30°C).240 Store and dispense in original package;240 do not remove desiccant;240 protect from moisture.240

Actions and Spectrum

  • Dolutegravir is an HIV INSTI antiretroviral.1 200 Inhibits activity of HIV integrase, an enzyme that integrates HIV DNA into the host cell genome.4 1 Inhibition of integrase prevents propagation of viral infection.1 4

  • Dolutegravir binds to active site of HIV integrase and blocks strand transfer step of retroviral DNA integration, which is essential for HIV replication.1

  • Active against HIV type 1 (HIV-1);1 also has in vitro activity against HIV type 2 (HIV-2).1 20 25 Not active against HCV.20

  • Has been active against HIV-1 resistant to HIV NRTIs, HIV nonnucleoside reverse transcriptase inhibitors (NNRTIs), or HIV protease inhibitors (PIs).1

  • HIV-1 resistant to dolutegravir have been produced in vitro and have emerged during dolutegravir therapy.1 12 13

  • Appears to have a different resistance profile than other HIV INSTIs and has been active in vitro against some HIV-1 resistant to other INSTIs (e.g., elvitegravir, raltegravir).1 12 13 14 15 16 However, cross-resistance between dolutegravir and other INSTIs (e.g., elvitegravir and/or raltegravir) reported.1 12 15 16

Advice to Patients

  • Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.1 200 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician.1 200 240

  • Importance of using single-entity dolutegravir (Tivicay) in conjunction with other antiretrovirals—not for monotherapy.1

  • Abacavir/dolutegravir/lamivudine (Triumeq) may be used alone as a complete regimen for treatment of HIV-1 infection or in conjunction with other antiretrovirals.240

  • Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.200

  • Advise patients that early initiation of antiretroviral therapy and sustained decreases in plasma HIV RNA have been associated with reduced risk of progression to AIDS and death.200

  • Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids) and reducing high-risk behaviors (e.g., never reusing or sharing needles).200

  • Importance of reading patient information provided by the manufacturer.1 240

  • If a dose of dolutegravir or abacavir/dolutegravir/lamivudine is missed and remembered ≥4 hours before the next scheduled time, the dose should be taken as soon as it is remembered and the next dose taken at the regularly scheduled time.1 240 If a missed dose of dolutegravir or abacavir/dolutegravir/lamivudine is remembered within 4 hours before the next dose is due, the dose should be skipped and the next dose taken at the regularly scheduled time.1 240 A double dose should not be taken to make up for a missed dose.1 240

  • Importance of immediately discontinuing dolutegravir and other suspect agents and seeking medical attention if rash occurs and is associated with fever, generally ill feeling, extreme tiredness, muscle or joint aches, breathing difficulty, blisters or peeling skin, oral blisters or lesions, eye inflammation, swelling of the face, eyes, lips, or mouth, and/or signs and symptoms of liver problems (e.g., yellowing of skin or whites of the eyes, dark or tea-colored urine, pale stools/bowel movements, nausea, vomiting, loss of appetite, or pain, aching, or sensitivity on the right side below ribs).1 240

  • Advise patients that hepatotoxicity has been reported in patients receiving dolutegravir and that monitoring for hepatotoxicity recommended.1 240

  • Advise patients that signs and symptoms of inflammation from previous infection may occur soon after initiation of antiretroviral therapy; importance of immediately informing clinician if any signs or symptoms of infection occur.1 240

  • Inform patients that redistribution/accumulation of body fat may occur with antiretroviral therapy, with as yet unknown long-term health effects.240

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal products, and any concomitant illnesses.1 240

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 240 (See Pregnancy under Cautions.) Advise HIV-infected women not to breast-feed.1 240

  • Importance of advising patients of other important precautionary information.1 240 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Dolutegravir Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

10 mg (of dolutegravir)

Tivicay

ViiV

25 mg (of dolutegravir)

Tivicay

ViiV

50 mg (of dolutegravir)

Tivicay

ViiV

Dolutegravir Sodium Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

50 mg (of dolutegravir) with Abacavir Sulfate 600 mg (of abacavir) and Lamivudine 300 mg

Triumeq

ViiV

50 mg (of dolutegravir) with Rilpivirine Hydrochloride 25 mg (of rilpivirine)

Juluca

ViiV

AHFS DI Essentials™. © Copyright 2018, Selected Revisions October 1, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. ViiV Healthcare. Tivicay (dolutegravir) tablets prescribing information. Research Triangle Park, NC; 2017 Nov.

2. Raffi F, Rachlis A, Stellbrink HJ et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381:735-43. http://www.ncbi.nlm.nih.gov/pubmed/23306000?dopt=AbstractPlus

3. Raffi F, Jaeger H, Quiros-Roldan E et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13:927-35. http://www.ncbi.nlm.nih.gov/pubmed/24074642?dopt=AbstractPlus

4. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369:1807-18. http://www.ncbi.nlm.nih.gov/pubmed/24195548?dopt=AbstractPlus

5. Feinberg J, Clotet B, Khuong-Josses MA, et al. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral-naive adults: 48 week results from FLAMINGO (ING114915). Paper presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sep 10–13, 2013; Denver CO. http://www.natap.org/2013/ICAAC/ICAAC_24.htm

6. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382:700-8. http://www.ncbi.nlm.nih.gov/pubmed/23830355?dopt=AbstractPlus

7. Song IH, Borland J, Chen S et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012; 56:1627-9. http://www.ncbi.nlm.nih.gov/pubmed/22183173?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3294934&blobtype=pdf

8. Song IH, Borland J, Chen S et al. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2013; 57:4394-7. http://www.ncbi.nlm.nih.gov/pubmed/23817375?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3754328&blobtype=pdf

9. Castellino S, Moss L, Wagner D et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013; 57:3536-46. http://www.ncbi.nlm.nih.gov/pubmed/23669385?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3719771&blobtype=pdf

10. Weller S, Borland J, Chen S et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2013; :. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3889630&blobtype=pdf

12. Deanda F, Hightower KE, Nolte RT et al. Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics. PLoS One. 2013; 8:e77448. http://www.ncbi.nlm.nih.gov/pubmed/24146996?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3797783&blobtype=pdf

13. Mesplède T, Quashie PK, Osman N et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013; 10:22. http://www.ncbi.nlm.nih.gov/pubmed/23432922?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3598531&blobtype=pdf

14. Canducci F, Ceresola ER, Saita D et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother. 2013; 68:2525-32. http://www.ncbi.nlm.nih.gov/pubmed/23798668?dopt=AbstractPlus

15. Abram ME, Hluhanich RM, Goodman DD et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother. 2013; 57:2654-63. http://www.ncbi.nlm.nih.gov/pubmed/23529738?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3716146&blobtype=pdf

16. Underwood MR, Johns BA, Sato A et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012; 61:297-301. http://www.ncbi.nlm.nih.gov/pubmed/22878423?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3804312&blobtype=pdf

17. Song I, Borland J, Chen S et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011; 72:103-8. http://www.ncbi.nlm.nih.gov/pubmed/21342217?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3141191&blobtype=pdf

18. Min S, Song I, Borland J et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010; 54:254-8. http://www.ncbi.nlm.nih.gov/pubmed/19884365?dopt=AbstractPlus

19. Patel P, Song I, Borland J et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011; 66:1567-72. http://www.ncbi.nlm.nih.gov/pubmed/21493648?dopt=AbstractPlus

20. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 204790Orig1s000: Microbiology review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000MicroR.pdf

21. Weller S, Chen S, Borland J et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014; 66:393-8. http://www.ncbi.nlm.nih.gov/pubmed/24798770?dopt=AbstractPlus

22. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014; 210:354-62. http://www.ncbi.nlm.nih.gov/pubmed/24446523?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4091579&blobtype=pdf

23. Akil B, Blick G, Hagins DP et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015; 20:343-8. http://www.ncbi.nlm.nih.gov/pubmed/25321146?dopt=AbstractPlus

24. Walmsley S, Baumgarten A, Berenguer J et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015; 70:515-9. http://www.ncbi.nlm.nih.gov/pubmed/26262777?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4645960&blobtype=pdf

25. Smith RA, Raugi DN, Pan C et al. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology. 2015; 12:10. http://www.ncbi.nlm.nih.gov/pubmed/25808007?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4328052&blobtype=pdf

26. Song I, Borland J, Chen S et al. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol. 2014; 70:1173-9. http://www.ncbi.nlm.nih.gov/pubmed/25146692?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4158172&blobtype=pdf

27. Song I, Borland J, Chen S et al. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother. 2014; 58:6696-700. http://www.ncbi.nlm.nih.gov/pubmed/25155604?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4249430&blobtype=pdf

28. Song I, Borland J, Arya N et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015; 55:490-6. http://www.ncbi.nlm.nih.gov/pubmed/25449994?dopt=AbstractPlus

29. Song IH, Borland J, Chen S et al. Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. Ann Pharmacother. 2015; 49:784-9. http://www.ncbi.nlm.nih.gov/pubmed/25862012?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4472613&blobtype=pdf

30. Song I, Weller S, Patel J et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol. 2016; 72:665-70. http://www.ncbi.nlm.nih.gov/pubmed/26898568?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4865535&blobtype=pdf

31. Song IH, Zong J, Borland J et al. The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. J Acquir Immune Defic Syndr. 2016; 72:400-7. http://www.ncbi.nlm.nih.gov/pubmed/26974526?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4935531&blobtype=pdf

32. Letendre SL, Mills AM, Tashima KT et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014; 59:1032-7. http://www.ncbi.nlm.nih.gov/pubmed/24944232?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4166983&blobtype=pdf

33. Molina JM, Clotet B, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015; 2:e127-36. http://www.ncbi.nlm.nih.gov/pubmed/26424673?dopt=AbstractPlus

35. US Food and Drug Administration. FDA drug safety communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). 2018 May 18. From FDA website. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM608127.pdf

109. Genentech USA, Inc. Pegasys (peginterferon alfa-2a) injection for subcutaneous use prescribing information. South San Francisco, CA; 2015 Mar.

176. Gilead Sciences. Epclusa (sofosbuvir and velpatasvir) tablets prescribing information. Foster City, CA; 2016 Jun.

177. Merck & Co., Inc. Zepatier (elbasvir and grazoprevir) tablets prescribing information. Whitehouse Station, NJ; 2016 Jan.

181. Gilead Sciences. Harvoni (ledipasvir and sofosbuvir) tablets prescribing information. Foster City, CA; 2016 Jun.

187. Janssen. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2016 Feb.

198. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. From HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV (May 30, 2018). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

201. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection (May 22, 2018). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

202. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for the use of antiretroviral drugs in women with HIV infection and interventions to reduce perinatal HIV transmission in the United States (May 20, 2018). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

203. HHS Antiretroviral Guideline Panels. Recommendations regarding use of dolutegravir in adults and adolescents with HIV who are pregnant or of child bearing potential (May 30, 2018). Updates may be available at HHS AIDS Information (AIDSinfo) website. https://aidsinfo.nih.gov/news/2109/recommendations-regarding-the-use-of-dolutegravir-in-adults-and-adolescents-with-hiv-who-are-pregnant-or-of-child-bearing-potential

237. Janssen Therapeutics. Prezcobix (darunavir/cobicistat) tablets prescribing information. Titusville, NJ; 2015 Jan.

240. ViiV Healthcare. Triumeq (abacavir, dolutegravir, lamivudine) tablets prescribing information. Research Triangle Park, NC; 2016 Apr.

247. ViiV Healthcare. Juluca (dolutegravir and rilpivirine) tablets prescribing information. Research Triangle Park, NC; 2017 Nov.

Hide